Incidence, prognosis, and risk factors of sepsis-induced cardiomyopathy

Table 2 Comparison of primary and secondary outcomes, n (%)

Outcome	Original patients (before matching)				PSM adjusted patients (after matching)
	Non-SIC (n = 2533)	SIC (n = 997)	OR (95%CI)	P value	Non-SIC (n = 809)	SIC (n = 809)	OR (95%CI)	P value
Hospital mortality	818 (32.3)	367 (36.8)	1.22 (1.05-1.42)	0.011	243 (30.0)	286 (35.4)	1.27 (1.03-1.57)	0.023
Mechanical ventilation use	1478 (58.3)	619 (62.1)	1.17 (1.01-1.36)	0.042	431 (53.3)	500 (61.8)	1.42 (1.16-1.73)	0.001
RRT use	290 (11.4)	116 (11.6)	1.02 (0.81-1.28)	0.876	91 (11.2)	94 (11.6)	1.04 (0.76-1.41)	0.815
Norepinephrine use	1276 (50.4)	589 (59.1)	1.42 (1.23-1.65)	0.000	433 (53.5)	474 (58.6)	1.23 (1.01-1.50)	0.040
Epinephrine use	63 (2.5)	62 (6.2)	2.59 (1.81-3.70)	0.000	25 (3.1)	46 (5.7)	1.88 (1.14-3.09)	0.012
Dopamine use	279 (11.0)	188 (18.9)	1.88 (1.54-2.30)	0.000	105 (13.0)	141 (17.4)	2.08 (1.08-1.86)	0.013
Vasopressin use	508 (20.1)	258 (25.9)	1.39 (1.17-1.65)	0.000	178 (22.0)	206 (25.5)	1.21 (0.96-1.52)	0.102
Length of ICU stay (d)
Overall	9.25 ± 11.66	9.11 ± 11.33	NA	0.749	9.35 ± 12.00	8.69 ± 9.74	NA	0.222
Survivors	8.82 ± 12.00	8.70 ± 11.77		0.827	8.71 ± 11.85	8.25 ± 9.55		0.479
Non-Survivors	10.15 ± 10.85	9.81 ± 10.51		0.616	10.82 ± 12.24	9.49 ± 10.03		0.167
Length of hospital stay (d)
Overall	24.83 ± 26.05	21.45 ± 20.84	NA	0.000	23.38 ± 23.01	21.22 ± 19.46	NA	0.042
Survivors	23.71 ± 23.69	21.92 ± 20.28		0.093	21.62 ± 19.17	21.40 ± 17.13		0.844
Non-Survivors	27.19 ± 30.29	20.61 ± 21.75		0.000	27.44 ± 29.69	20.84 ± 23.13		0.004

Vasopressor use including the use of norepinephrine, epinephrine, dopamine, or vasopressin. SIC: Sepsis-induced cardiomyopathy; PSM: Propensity score matching; RRT: Renal replacement therapy; ICU: Intensive care unit; NA: Not available.